Literature DB >> 1685032

Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories.

S Caldecott-Hazard1, D G Morgan, F DeLeon-Jones, D H Overstreet, D Janowsky.   

Abstract

The present document is the second of three parts in a review that focuses on recent data from clinical and animal research concerning the biochemical bases of depressive disorders, diagnosis, and treatment. Various receptor/transmitter theories of depressive disorders are discussed in this section. Specifically, data supporting noradrenergic, serotonergic, cholinergic, dopaminergic, GABAergic, and peptidergic theories, as well as interactions between noradrenergic and serotonergic, or cholinergic and catecholaminergic systems are presented. Problems with the data and future directions for research are also discussed. A previous publication, Part I of this review, dealt with the classification of depressive disorders and research techniques for studying the biochemical mechanisms of these disorders. A future publication, Part III of this review, discusses treatments for depression and some of the controversies in this field.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685032     DOI: 10.1002/syn.890090404

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  19 in total

1.  Effects of milnacipran in animal models of anxiety and memory.

Authors:  Vânia K M Moojen; Márcio Rodrigo Martins; Adalisa Reinke; Gustavo Feier; Fabiano R Agostinho; Edson M Cechin; João Quevedo
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

2.  Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study.

Authors:  P A Boyer; P Skolnick; L H Fossom
Journal:  J Mol Neurosci       Date:  1998-06       Impact factor: 3.444

Review 3.  The effects of stress on central dopaminergic neurons: possible clinical implications.

Authors:  J M Finlay; M J Zigmond
Journal:  Neurochem Res       Date:  1997-11       Impact factor: 3.996

4.  Behaviour of a genetic mouse model of depression in the learned helplessness paradigm.

Authors:  Laure Bougarel; Jérôme Guitton; Luc Zimmer; Jean-Marie Vaugeois; Malika El Yacoubi
Journal:  Psychopharmacology (Berl)       Date:  2011-02-22       Impact factor: 4.530

Review 5.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

6.  Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine.

Authors:  E Le Poul; N Laaris; E Doucet; A M Laporte; M Hamon; L Lanfumey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

7.  Pharmacologic specificity of antidepressive activity by monoaminergic neural transplants.

Authors:  D D Dougherty; C E Sortwell; J Sagen
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

8.  Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man.

Authors:  P M Grasby; K J Friston; C Bench; P J Cowen; C D Frith; P F Liddle; R S Frackowiak; R J Dolan
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes.

Authors:  Mark J Millan; Sylvie Veiga; Sylvie Girardon; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

10.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.